Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2017 Feb 2;37(4):664–674. doi: 10.1161/ATVBAHA.116.308791

Figure 4. Tamoxifen decreases the metastatic potential of platelets.

Figure 4

To determine the metastatic potential of tamoxifen-treated platelets, releasates were generated as described in Figure 3A and used in standard transwell invasion assays. The ability of MCF-7 tumor cells to invade through Matrigel in response to platelet releasates was quantified (A) and representative images are shown (B). Transendothelial migration assays were performed in which MCF-7 tumor cells cross an endothelialized transwell membrane in the presence or absence of live platelets pretreated with 0 or 20 µM tamoxifen (C). Bars indicate SEM. P<*0.05, **0.01 by ANOVA, n=3–5 independent replicates per treatment group. Scale bars represent 100 µm.